Maine Medicine Weekly Update - June 19 - June 26  (Plain Text Version)

Return to Graphical Version

 

In this issue:
•  Registration open for MMA’s 168th Annual Membership Meeting (Sep 10-12)
•  FDA to revise vaccine fact sheets on increased risk of myocarditis
•  MaineCare announces continuation of policies upon end of Civil Emergency
•  Maine Secretary of State seeking physician volunteers
•  Maine DHHS announces free text alert program to prevent overdose deaths
•  Associated Press: Nearly all COVID deaths in US are now among unvaccinated
•  AAMC Report Reinforces Mounting Physician Shortage
•  #VaccinateME - Maine Community Action Partnership: #GiveitaSHAHT!
•  Top JAMA and JAMA Network articles
•  MMA Mary Cushman, MD Award for Humanitarian Service
MAINE LEGISLATURE
•  Legislative Advocacy Update: Maine Legislature returns this week
Federal Government Affairs
•  Federal Advocacy Scan: Infrastructure spending bill caught up in political fight
UPCOMING EVENTS
•  Upcoming Specialty Society Meetings
•  AAP EQIPP Course: Immunizations - Strategies for Success (for RURAL Health Providers)
•  SUPPORT for ME Training and Technical Assistance Initiative
•  Working with Children & Adolescents? Maine Pediatric & Behavioral Health Partnership (MPBHP) Webinar Series (July thru December 2nd Wednesday of month)
•  Register Now: Governor Mills’ 3rd Annual Opioid Response Summit on July 15th
• 
HEALTHCARE EMPLOYMENT OPPORTUNITIES
•  Physician (BC/BE in Family Medicine) - Strong Area Health Center
•  Physician (BC/BE in Family Medicine) - Richmond Area Health Center
•  Contract Clinical Advisor - Healthcare Coalition of Maine
•  Medical Director
•  Pediatrician

 

FDA to revise vaccine fact sheets on increased risk of myocarditis

FDA to revise vaccine fact sheets on increased risk of myocarditis

The FDA announced Friday they will revise the patient and provider fact sheets for the Moderna and Pfizer-BioNTech COVID-19 vaccines regarding the suggested increased risks of myocarditis and pericarditis following vaccination.

The FDA announced Friday they will revise the patient and provider fact sheets for the Moderna and Pfizer-BioNTech COVID-19 vaccines regarding the suggested increased risks of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart) following vaccination.

The decision comes after the CDC Advisory Committee on Immunization Practices (ACIP) on Wednesday identified a “likely association” between the two mRNA vaccines and cases of myocarditis and pericarditis.

According to the FDA, the update follows an extensive review of information and the discussion by CDC’s Advisory Committee on Immunization Practices meeting on Wednesday.

·   Reports describe the illness predominantly in males under 30 followingthe second dose of an mRNA vaccine, with most cases appearing to resolve themselves.

·    More than 150 million people have received either the Pfizer or Moderna vaccine, making the 1,200-plus documented cases rare.

·    The warning in the Fact Sheets for Healthcare Providers Administering Vaccines notes that reports of adverse events suggest increased risks of myocarditis and pericarditis, particularly following the second dose and with onset of symptoms within a few days after vaccination.

·   Recipients and Caregivers for these vaccines note that vaccine recipients should seek medical attention right away if they have chest pain, shortness of breath, or feelings of having a fast-beating, fluttering, or pounding heart after vaccination.

·    The FDA and CDC are monitoring the reports, collecting more information, and will follow-up to assess longer-term outcomes over several months.

NBC News: Benefits of COVID-19 vaccination outweigh risks of heart inflammation in young people